Johnson & Johnson Launches Next-Generation Coronary IVL Catheter Shockwave C2 Aero Globally

May 14, 2026 07:30 CST Updated 07:30

Johnson & Johnson

Medical Device R&D and Manufacturer

Stryker

Medical Device R&D, Production, and Sales Company

[Editor's Note]May 12th, Johnson & Johnson globally launched its new-generation intravascular lithotripsy catheter, Shockwave C2 Aero. Coincidentally, on May 11th, another global medical device giant, Stryker, announced an acquisition of Amplitude Vascular Systems, a rising company in IVL, for up to $835 million.In just a few days, the "lithotripsy" track in the field of coronary and peripheral interventions has become highly competitive.

Johnson & Johnson announced the official launch worldwideShockwave C2 Aero Coronary Intravascular Lithotripsy Catheter。

This new-generation catheter not only inherits the unique mechanism of action, widely recognized safety, and effectiveness of the previous Shockwave IVL catheter but also achieves three major core technology upgrades:Better deliverability, stronger cross-lesion capability, and a brand-new repositioning function. The launch of this coronary catheter further expands Johnson & Johnson's leading IVL product line in the field of coronary artery calcified lesion treatment.

Breaking Through Anatomical Limitations: More Flexible and Efficient Treatment StrategiesJohnson & Johnson stated that the Shockwave C2 Aero will provide clinicians with greater flexibility and extremely high efficiency when formulating treatment strategies.

Ultimate Delivery:With a softer catheter guidewire lumen, balloon, and marker band design, the new-generation catheter demonstrates excellent deliverability when navigating through extremely narrow and tortuous arterial vessels.
Breaking the Ice:With a newly designed tapered tip and an upgraded hydrophilic coating, the catheter can more easily enter and penetrate dense calcified deposits.
Freehand Repositioning:Thanks to a new balloon material that allows for more compact shrinkage/folding, the catheter can be repositioned within complex coronary anatomies and confidently address additional lesions.

Core Technical Parameters and Market Launch PlanThe working length of the catheter is 138 centimeters. Inside its integrated balloon are two pulse emitters that can be synchronously triggered to deliver up to 120 pulses, generating as many as 240 "shock waves." Each shock wave pulse produces ultrasonic pressure waves that penetrate soft tissue, precisely shattering in-situ hardened calcified lesions and helping restore blood flow in blocked arteries.

Currently, Johnson & Johnson has taken the lead in launching Shockwave C2 Aero in the U.S. and Japanese markets and plans to enter the European and Canadian markets in the coming months.

The launch of this product comes at a time when the IVL sector is continuously heating up. Since Johnson & Johnson's acquisition of Shockwave for a staggering $13.3 billion in 2024, it has been leading the field. Meanwhile, competition has become extremely fierce: just last week, Stryker completed its acquisition of Amplitude Vascular Systems (AVS);

Boston Scientific also acquired Bolt Medical last year. In addition, Abbott is developing its own IVL system, while emerging companies such as FastWave Medical, Elixir Medical, and Vantis Vascular are actively advancing their respective IVL platforms.

Voices of Senior and Clinical ExpertsIsaac Zacharias, President of Johnson & Johnson Medical Technologies' Shockwave Division, stated:"We are redefining the standard for coronary IVL. In the most critical and challenging cases, we are committed to providing a more efficient and predictable overall surgical solution. As other competitors prepare to enter the coronary IVL market, Johnson & Johnson has once again raised the industry bar with our fifth-generation platform. This is based on years of physician feedback, continuous R&D investment, and rigorous clinical validation of our unique mechanism of action, all of which further solidify our leadership position in IVL."

Benjamin Honton, a cardiovascular interventional expert at the Pasteur Clinic in Toulouse, France, commented:"In previous iterations of IVL technology, physicians often required additional auxiliary devices to achieve optimal positioning. Moreover, the treatment of coronary lesions was typically limited to a single operational path of 'from distal to proximal.' However, the outstanding balloon folding and retraction capability of the Shockwave C2 Aero makes repositioning exceptionally easy, allowing the catheter to move both forward and backward within the vessel, and even to cross the lesion again if needed. This remarkable flexibility aids us in addressing more complex calcification patterns and supports a more personalized pulse delivery strategy (including multi-vessel lesions), significantly expanding the clinical application boundaries of intravascular lithotripsy."

Margaret McEntegart, MD, Director of the Complex PCI Program at NewYork-Presbyterian Hospital/Columbia University Medical Center, believes:"Shockwave C2 Aero allows us to navigate more easily through tortuous coronary anatomies without relying on additional assistive devices upfront. This enhanced deliverability and efficiency are enough to change the usage habits of IVL and increase its weight in treatment algorithms. Johnson & Johnson is continuously addressing the pain points clinicians face in real-world scenarios—such as deliverability, penetration, and repositioning capabilities—redefining industry expectations for the performance of this technology in complex PCI procedures."

Why Has the IVL Track Completely Boomed?

1. Clinical pain points determine market value: "Whoever masters calcification rules the world."Whether it is complex PCI for coronary arteries or endovascular treatment for lower extremity arteriosclerosis obliterans commonly performed in vascular surgery,Severe calcification (especially circular, eccentric, and nodular calcification) has always been the toughest challenge in interventional procedures.Traditional balloons can easily lead to vascular dissection or even rupture, while plaque excision devices carry the risk of distal embolism and vascular perforation. The emergence of IVL technology is a game-changer with its "hard-targeting yet soft-sparing" feature perfectly protecting the normal vascular intima. Johnson & Johnson and Stryker, two industry giants, have invested billions and hundreds of millions of dollars respectively in acquisitions, precisely because they recognize this irreplaceable clinical necessity.

2. Johnson & Johnson C2 Aero Hits the "Pain Point" of Vascular Surgeons' Practical OperationsWhat is the biggest苦恼 when performing IVL? It's "unable to enter."And"Can't get out." Previous catheters were relatively stiff, making it difficult to cross extremely tortuous lesions; once shockwave was released in a target vessel, the balloon material would deform, making it extremely challenging to push it back in to treat another lesion. This upgrade of C2 Aero – a softer shaft, tapered tip, and new balloon folding technology – effectively addresses these practical pain points. It allows us to repeatedly advance and retract a single catheter for positioning across multiple vessels or different calcified segments within the same vessel, which not only significantly saves operation time but also reduces the financial burden of consumables on patients.

3. Stryker Acquires AVS for $835 Million: A "Technological Breakthrough" in the Peripheral MarketIf Johnson & Johnson's C2 Aero is inCoronary BattlefieldTo consolidate its dominant position, Stryker's high-priced acquisition of AVS is a move targetingPeripheral Vascular Battlefield's precision sniping. The Pulse IVL platform of AVS is different from Shockwave's traditional spark discharge-generated shockwaves, as it adoptsPulsed CO2 Generates Pressure WavesThis innovative physical mechanism is claimed to deliver energy more evenly along the entire length of the balloon, and without the need for poles inside the catheter, it may achieve new breakthroughs in catheter outer diameter and flexibility. For us vascular surgeons dealing with long, multi-segment calcified femoral-popliteal or infrapopliteal arteries, the potential of this technology is immeasurable.

4. "Hundred Regiments Offensive" Launches, Ultimately Benefiting PatientsFrom Johnson & Johnson, Boston Scientific, Abbott, to today's Stryker, the world's four major cardiovascular intervention giants have all heavily gathered in the IVL track. In addition to overseas giants, China's domestic medical device enterprises (such as Jianshi, Yuanda, etc.) are also accelerating the research and development and iteration of local IVL products. The capital frenzy will eventually translate into technological accessibility. The intensification of competition means that the performance of IVL catheters will become increasingly excellent, and prices are also expected to gradually break through monopoly barriers. As clinical doctors, we look forward to these more deliverable, smarter, and more economical "calcium-breaking tools" fully entering the Chinese clinical field as soon as possible, opening up life channels for a large number of patients with severe vascular calcification!

Copyright Statement: This platform aims to help healthcare professionals better understand the latest developments in relevant disease areas. The platform does not necessarily agree with the descriptions and viewpoints of the published information, but merely provides more information. If there are any copyright issues, we kindly request the rights holders to contact us, and we will address them as soon as possible. The information is intended solely for healthcare professionals to stay informed, and such information should not replace professional medical guidance in any way, nor should it be considered as medical advice. If such information is used for purposes other than staying informed, this platform and the author shall not bear any related responsibility.Contact email for cooperation:vascular@edoctor.work。

Go to Mini Program